Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 2014

View Archived Issues

ArmaGen Technologies' re-engineered IDS penetrates BBB

Protalix BioTherapeutics presents new preclinical data on PRX-102

Catalent forms regenerative therapy agreement with Kyoto University

Proteostasis Therapeutics presents data on novel USP14 inhibitor

Medinet establishes partnership with TC BioPharm for immuno-cell product

AstraZeneca and Osaka University to collaborate on repurposing drugs for cardiovascular disease

Purdue Pharma reports phase III data for once-daily hydrocodone bitartrate

Formycon advances biosimilar pipeline

Gilead Sciences plans phase I study of GS-5745 in COPD

Peregrine Pharmaceuticals' PS-targeted programs supported by recent preclinical data

Pluristem Therapeutics reports preclinical data on PLX-PAD cells for tendon injury

Progression-free survival improved with fosbretabulin added to bevacizumab in ovarian cancer

GSK reports phase III data for mepolizumab in severe eosinophilic asthma

Researchers identify a new putative compensatory mechanism of miR1246 in colorectal cancer

JDP Therapeutics receives FDA clearance for phase III trial of JDP-205 in acute urticaria

GlaxoSmithKline and Theravance complete enrollment in SUMMIT study

Novartis discloses new mGlu5 receptor antagonists

Favorable 24-week virological efficacy of BMS-663068 supports continued development

GlaxoSmithKline patent reports new anti-LRP-6 antibodies

Daiichi Sankyo designs new chromone derivatives for osteoporosis and bone fractures

Potent antiviral activity and favorable safety of doravirine in HIV-1-infected patients

Idera plans to initiate clinical development of IMO-8400 in two new indications

GSK-744/rilpivirine as maintenance therapy for HIV infection

High early bactericidal activity of pretomanid combined with bedaquiline and pyrazinamide

Knopp enters new NIAID collaboration to investigate eosinophil-lowering effects of dexpramipexole

FDA accepts Envarsus NDA for review

Novartis' Bexsero obtains clinical recommendation in Australia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...